Economic cost of age-related macular degeneration: a review of recent research

Kathleen Ke, Usha Chakravarthy, C. O'Neill

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


As the population of most developed countries ages so the prevalence of diseases such as age-related macular degeneration (AMD) are likely to increase. To facilitate planning and informed debate regarding making provisions for this disease it is important that we have a clear understanding of the economic impact of visual impairment associated with AMD. In this paper we assess the state of current knowledge based on a review of published evidence in scientific journals. Based on our assessment of the evidence we argue that the paucity of research studies on the subject and wide variation in estimates produced from the few studies available make it difficult to assess with confidence the likely average direct cost-of-illness associated with AMD. We further argue that significant gaps in our understanding of the costs of AMD (particularly in respect of indirect costs) also exist. Current research should be augmented by more comprehensive studies.
Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalDrugs and Ageing
Issue number3
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology


Dive into the research topics of 'Economic cost of age-related macular degeneration: a review of recent research'. Together they form a unique fingerprint.

Cite this